Laugh your way to better eyes? trial tests fun fixes for dry eye

NCT ID NCT07524725

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two behavioral interventions—Baduanjin (a gentle 10-15 minute exercise) or laughter exercises using a smartphone app—plus artificial tears, against artificial tears alone for treating dry eye disease. About 540 adults aged 18-45 with moderate dry eye will participate for 12 weeks, with follow-ups up to 48 weeks. The main goal is to see if these activities improve eye discomfort and vision-related quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Baduanjin (a gentle exercise routine) and laughter exercise (facial movements guided by a smartphone app), plus artificial tears

What this could lead to

If it works, this could offer simple, drug-free ways to ease dry eye symptoms.

What could go wrong

This is an early-stage trial with no phase, and the benefits may be small or not last long. The exercises require regular commitment, which may be hard for some people to maintain.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE DISEASE (DED) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

dry eye syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••